Business Context and Reporting Period
Company: Centene Corporation
Filing Type: Form 8-K (Current Report)
Date: July 23, 2024
Subject: Results of Operations and Financial Condition regarding the final 2023 Benefit Year Risk Adjustment transfers published by the Centers for Medicare and Medicaid Services (CMS) on July 22, 2024.
Key Financial Metrics
Risk Adjustment Impact (2023 Benefit Year):
- Final CMS Receivable: $0.0 billion.
- Previously Recorded Payable (as of March 31, 2024): $1.3 billion (net).
- Net Outperformance Recorded in Q2 2024: $0.7 billion (after offsets for Minimum Medical Loss Ratio payable and competitor insolvency).
- Estimated Full Year 2024 Net Outperformance: $0.6 billion.
- GAAP Diluted EPS: $2.16.
- Adjusted Diluted EPS: $2.42.
- GAAP Diluted EPS: Greater than $5.94.
- Adjusted Diluted EPS: Greater than $6.80.
- Amortization of acquired intangible assets: $0.33 per share.
- Acquisition and divestiture related expenses: $0.01 per share.
- Other adjustments: $0.00 per share (includes gains/losses on divestitures of Circle Health, Spanish/Central European businesses, and restructuring severance).
Material Changes vs. Prior Period
The primary material change is the resolution of the 2023 Benefit Year risk adjustment. Centene had recorded a $1.3 billion net payable as of March 31, 2024. The final CMS determination resulted in a $0.0 billion receivable, creating a $1.3 billion favorable variance. After accounting for a $0.3 billion increase in Minimum Medical Loss Ratio (MLR) payable and $0.3 billion in estimated offsets due to competitor insolvency, the company recognized a net outperformance of $0.7 billion in Q2 2024. This outperformance is expected to increase the MLR payable for the 2024 benefit year by approximately $0.1 billion in the second half of 2024.
Guidance, Outlook, and Risks
Outlook and Guidance:
The company expects to reaffirm its full-year 2024 guidance floor of greater than $5.94 GAAP diluted EPS and greater than $6.80 adjusted diluted EPS during its earnings call on July 26, 2024. The Q2 results include the $0.7 billion risk adjustment outperformance.
Management Commentary:
Management utilizes non-GAAP measures to assess core business operations, excluding amortization of acquired intangibles and transaction-related expenses. The filing notes that actual Q2 results may differ from these preliminary estimates.
Risks and Contingencies:
The filing includes extensive forward-looking statement disclaimers. Key risks cited include:
- Ability to design competitive products and manage medical utilization rates.
- Changes in CMS Star ratings and quality scores impacting revenue.
- Regulatory changes, including Medicaid redeterminations and ACA regulations.
- Government shutdowns, debt ceilings, or funding uncertainties.
- Legal or regulatory audits and investigations.
- Cyber-attacks and data security incidents.
- Impairments to assets and changes in provider contracts.
Investor Verification Checklist
- Verify the final Q2 2024 earnings release on July 26, 2024, to confirm the preliminary EPS figures of $2.16 (GAAP) and $2.42 (Adjusted).
- Confirm the full-year 2024 guidance reaffirmation during the earnings call.
- Monitor the impact of the $0.1 billion increase in MLR payable on H2 2024 results.
- Review the reconciliation of non-GAAP items for specific details on divestiture gains/losses (e.g., Magellan Specialty Health, Circle Health) and asset impairments (e.g., Health Net Federal Services).
- Assess ongoing regulatory risks related to Medicaid redeterminations and CMS Star ratings.